Table 4 : Statistical summary of differences in spectral intensity for SELDI-TOF MS spectra (A-II monomer and Apo A-II dimer) between GDM cases and gestationally age matched controls.


Apo A-II monomer (µA)

  4-12 weeks* 16-22 weeks* 24-28 weeks* P value **
(16-22, 24-28 weeks)
U value (critical U)***
(16-22, 24-28 weeks)

Control 109 (9) 140 (34) 140 (34) 0.033, 0.012 14 (15), 10(15)
Gestational Diabetes 115 (20) 110 (22) 143 (41) 0.417, 0.201 11 (4), 8 (7)

Apo A-II monomer (µA)

  4-12 weeks* 16-22 weeks* 24-28 weeks* P value **
(16-22, 24-28 weeks)
U value (critical U)***
(16-22, 24-28 weeks)

Control 65 (6) 57 (6) 61 (13) 0.735, 0.397 25 (15), 29 (15)
Gestational Diabetes 57(8) 40 (9) 46 (5) 0.011, 0.082 1 (4), 10 (9)

Data are expressed as median spectral intensities (µA) (median [95% confidence interval]) , n=4-5 GDM cases and n=8 gestationally age-matchedcontrols.
*median (95% confidence interval).
**, Mann-Whitney U test relative to 4-12 weeks.
***, critical value of u for statistical significance at p ≤0.05.

Ippolito et al.Journal of Diabetes Research and Clinical Metabolism  2013 2:22DOI : 10.7243/2050-0866-2-22